OSU-03012, also known as AR-12, is an orally active pyruvate dehydrogenase kinase isoenzyme 1 (PDK-1) and protein kinase B (AKT) signaling pathway inhibitor that reached Phase 1 clinical trials as a potential cancer therapeutic. Here, AKT1 is linked to cancer.